ArticleEJNMMI research2026

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience.

Niklas Ebert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.